Laboratory support in the diagnosis of XXXX .

@entity1 @entity132 @entity1112 @entity1252 @entity1003 @entity3459 @entity1200 @entity4461 @entity715
In spite of recent advances in knowledge concerning the detailed biochemistry of @entity1003 , the diagnosis of @entity132 remains an important problem of clinical judgement in many instances. Laboratory support relies initially on a series of screening tests designed to investigate the general nature of @entity4461 . Recent interest in these aspects is centred on standardization and quality assurance of methods and results. Procedures have been recommended in an attempt to unify data. Several aspects of conventional laboratory investigations have been modified and the reliability of diagnostic information has been improved. Some relatively recent findings have extended the application to coagulation studies. For example, the discovery of protein C, a potent physiological inhibitor of @entity1003 , has clarified the nature of the @entity4461 in some @entity1 with @entity715 . In addition, close analysis of plasma from @entity1 with @entity1252 has stimulated interest in the association between the haemostatic, neurological and @entity1200 recorded in these @entity1 . More recently, sophisticated techniques for the diagnosis of @entity3459 factor defects have been developed. Carrier detection of the @entity1112 is undertaken widely with reasonable success and reliable prenatal diagnosis procedures have been established in specialized centres. Unequivocal information regarding the diagnosis of carrier status in some families is obtained by the use of gene analysis and linked polymorphisms. Precise details of the genes for several clotting factors have been recorded. Future development in this field is likely to improve the clinical course of many @entity3459 .
